Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study is evaluating the Pharmacokinetics of MNTX in healthy control subjects and in
patients with mild, moderate, or severe renal impairment who do not require hemodialysis.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.